Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study

Wei Wang†, Xueyan Zhang†, Xiaoyan Bai‡, Yingkui Zhang‡, Ziyu Yuan†, Hefei Tang†, Zhiye Li‡, Zhangxuan Hu§, Yaqing Zhang†, Xueying Yu†, Binbin Sui‡* and Yonggang Wang†*

Abstract

Background: The pathogenesis of migraine chronification remains unclear. Functional and structural magnetic resonance imaging studies have shown impaired functional and structural alterations in the brains of patients with chronic migraine. The cerebellum and periaqueductal gray (PAG) play pivotal roles in the neural circuits of pain conduction and analgesia in migraine. However, few neurotransmitter metabolism studies of these migraine-associated regions have been performed. To explore the pathogenesis of migraine chronification, we measured gamma-aminobutyric acid (GABA) and glutamate/glutamine (Glx) levels in the dentate nucleus (DN) and PAG of patients with episodic and chronic migraine and healthy subjects.

Methods: Using the MEGA-PRESS sequence and a 3-Tesla magnetic resonance scanner (Signa Premier; GE Healthcare, Chicago, IL, USA), we obtained DN and PAG metabolite concentrations from patients with episodic migraine (n = 25), those with chronic migraine (n = 24), and age-matched and sex-matched healthy subjects (n = 16). Patients with chronic migraine were further divided into those with (n = 12) and without (n = 12) medication overuse headache. All scans were performed at the Beijing Tiantan Hospital, Capital Medical University.

Results: We found that patients with chronic migraine had significantly lower levels of GABA/water (p = 0.011) and GABA/creatine (Cr) (p = 0.026) in the DN and higher levels of Glx/water (p = 0.049) in the PAG than healthy controls. In all patients with migraine, higher GABA levels in the PAG were significantly associated with poorer sleep quality (GABA/water: r = 0.515, p = 0.017, n = 21; GABA/Cr: r = 0.522, p = 0.015, n = 21). Additionally, a lower Glx/Cr ratio in...
the DN may be associated with more severe migraine disability ($r = -0.425, p = 0.055, n = 20$), and lower GABA/water ($r = -0.424, p = 0.062, n = 20$) and Glx/Water ($r = -0.452, p = 0.045, n = 20$) may be associated with poorer sleep quality.

**Conclusions:** Neurochemical levels in the DN and PAG may provide evidence of the pathological mechanisms of migraine chronification. Correlations between migraine characteristics and neurochemical levels revealed the pathological mechanisms of the relevant characteristics.

**Keywords:** Magnetic resonance spectroscopy, Migraine chronification, Gamma-aminobutyric acid, Glutamate/glutamine, Dentate nucleus, Periaqueductal gray

**Background**
Migraine is a common disabling brain disorder that affects approximately 14% of the general population worldwide (males 8.6%, females 17.0%) [1]. This disease is typically characterized by moderate or severe headaches, and patients often experience additional symptoms such as nausea, phonophobia, and photophobia that last from 4 to 72 h. According to the International Classification of Headache Disorders, 3rd edition (ICHD-3) diagnostic criteria, migraine is divided into episodic migraine (EM) and chronic migraine (CM) [2]. Most patients have EM; however, up to 5% of patients may develop CM (headache occurring 15 or more days per month for more than 3 months that have the features of migraine headache at least 8 days per month) [2]. At least 50% of patients with CM regularly overuse one or more drugs for acute migraine treatment, thus resulting in the diagnosis of CM with medication overuse headache (MOH) [3]. CM often affects people during their most productive years of life, exerts substantial individual and societal costs, and is associated with numerous comorbid disorders [4]. The pathogenesis of CM and the mechanisms leading to its transformation remain unclear. Current theories include atypical pain processing, genetic and epigenetic factors, central sensitization, cortical hyperexcitability, and neurogenic inflammation [5]. Genetic studies have revealed the potential involvement of glutamatergic and GABAergic receptors in the pathogenesis of migraine [6–8]. Additionally, some studies have shown that hyperexcitability in the cortex [9–13], suggests that an unbalanced inhibition-excitation system in the brain contributes to the pathophysiology of migraines. However, the specific roles of glutamate and glutamine (Glx) and gamma-amino-butyric acid (GABA), which are the major excitatory and inhibitory neurotransmitters in the brain, in migraine are not fully understood.

During the past two decades, numerous structural and functional magnetic resonance imaging (MRI) studies have shown that the pathological mechanism of migraine is closely related to abnormalities in the central nervous system [14]. Magnetic resonance spectroscopy (MRS) is a noninvasive method that allows the investigation of brain metabolism. Several studies have used MRS to investigate metabolic changes in the brain regions and nuclei of patients with migraine [15]. The periaqueductal gray (PAG) is one of the most significant elements of the endogenous descending modulatory system, and numerous MRI studies have shown that the PAG has structural and functional abnormalities in patients with migraine [14, 16, 17]. The cerebellum has been implicated in various forms of motor control and coordination; however, more recently, it has also been suggested to have a role in nonmotor functions, including cognition and pain processing [18]. Currently, Glx and GABA in the cerebellum and PAG of patients with migraine have not been studied. Therefore, we used proton MRS ($^{1}$H-MRS), specifically the MEGA-PRESS technique, to explore the GABA and Glx levels in the PAG and dentate nucleus (DN), which is the largest nucleus in the cerebellum, of patients with EM and CM. Our primary aim was to determine whether there is an association between changes in GABA and Glx levels and EM and CM to further elucidate the role of neurotransmitters in migraine chronification. The secondary aim was to explore the differences in GABA and Glx levels of patients having CM with and without MOH to further elucidate the effects of medication overuse on neurotransmitters.

**Methods**
**Study design**
This study used a cross-sectional, case–control design and MRS to measure GABA and Glx levels of patients with EM and CM and healthy control subjects. Ethical approval was granted by Beijing Tiantan Hospital, Capital Medical University (no. KY2022-044). Written consent was obtained from participants in accordance with the principles of the Declaration of Helsinki.

**Participants**
We prospectively recruited 22 healthy subjects and 62 patients diagnosed with EM ($n = 29$) and CM ($n = 33$) from October 2020 to December 2021 at the Headache Center, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University. EM and CM (with and without MOH) were diagnosed according to the ICHD-3
Magnetic resonance imaging and spectroscopy

MR imaging was performed on a 3 T MR scanner (Signa Premier, GE Healthcare) using a 48-channel head coil. Patients were instructed to keep their head and neck stable, stay awake, close the eyes, and relax during the magnetic resonance (MR) scans. Scanning was performed using a 3-T MR scanner (Signa Premier, GE Healthcare) and a 48-channel head coil. T1-weighted volumetric images were acquired using the MP-RAGE sequence with 1-mm isotropic resolution (sagittal acquisition: field of view, 256 mm; acquisition matrix, 256; slice number, 192; flip angle, 8°; preparation time, 880 ms; recovery time, 400 ms; acceleration factor, 2; acquisition time, 4:00). Two 20 × 20 × 20 mm³ voxels were placed in PAG (Fig. 1Aa) and DN (Fig. 1Ab) respectively. The ¹H spectrum optimized for detecting GABA was acquired individually for these voxels using the MEGA-PRESS sequence with the following parameters: echo time/repetition time, 68/2000 ms; number of points, 2048; spectral width, 2000 Hz; and number of averages, 160 (scan time, 11 min 28 s). The MEGA-PRESS data were analyzed using the GABA analysis toolkit (GANNET3.1; http://gabamrs.org) [23], which uses a Gaussian baseline model to fit the edited GABA signal and a Lorentz-Gaussian line shape to fit the unsuppressed water signal. The processing steps were as follows: combination of phased array coil data; time-domain frequency and phase correction using spectral correction; exponential apodization function (line broadening); fast Fourier transform; time averaging; frequency and phase correction based on fitting of the water and creatine (Cr) signals; and pairwise rejection of data for which fitting parameters were greater than three standard deviations from the mean; and subtraction to generate the edited difference spectrum (and extraction of the OFF spectrum). The output GABA and Glx concentrations were expressed in international units relative to water (GABA and Glx/water) and as an integral ratio relative to Cr (GABA/Cr and Glx/Cr). Voxels were co-registered for T1-weighted structural acquisition. The detailed process is shown in Fig. 1B. The spectra were visually examined for artifacts by two specialists (W.W. and X.Y.Z.). MRS data were excluded if they demonstrated significant motion artifacts or insufficient water suppression. Finally, data that met our quality criteria were included in the analysis.

Statistical analysis

Normally distributed data are presented as the mean ± standard deviation. For continuous data comparisons among the three groups (healthy control, EM, and CM groups), a one-way analysis of variance and a post hoc analysis with the least significant difference method were performed. An independent samples t-test was applied to compare the two groups (EM and CM groups). Relationships between local GABA and/or Glx concentrations and headache characteristics were determined using Person’s correlation. The positive and negative correlation coefficients (r) represent positive and negative correlations. Statistical significance was set at P < 0.05. All statistical data were analyzed using SPSS software for Windows version 25.0 (SPSS Inc., Chicago, IL, USA).

Results

Demographics and clinical characteristics

Sixteen control group participants, 25 EM group participants, and 24 CM group participants (12 with MOH and 12 without MOH) were included. Six control participants were excluded owing to incomplete MRS data (n = 2) and poor quality (n = 4). Four EM patients were excluded owing to incomplete MRS data (n = 1), poor quality (n = 1) and combined with other types of primary headaches (n = 2). Nine CM patients were excluded owing to poor quality data (n = 6) and combined with other types of primary headaches.
All participants were right-hand-dominant. The demographic and clinical characteristics of the different groups are shown in Tables 1 and 2. Compared to patients with EM, those with CM had more headache days ($p < 0.001$) and more severe disability, as assessed by the MIDAS ($p = 0.033$). Patients with CM and MOH had a longer disease duration ($p = 0.034$) and higher headache frequency ($p = 0.018$) than patients having CM without MOH. There were no significant differences in other characteristics of the groups.

**Brain neurochemical levels in the control, EM, and CM groups**

The neurochemical levels in the PAG and DN of the three groups are shown in Fig. 3. Our results showed that the GABA/water and GABA/Cr levels were not significantly different in the PAG of the control, EM, and CM groups. However, the levels of GABA/water ($p = 0.011$) and GABA/Cr ($p = 0.026$) in the DN of the CM group were significantly lower than those of the control group. Our results also showed that Glx/water and Glx/Cr levels were not significantly different in the DN of the control, EM, and CM groups.
Fig. 2 Flow of the participants during the study. Abbreviations: CM, chronic migraine; EM, episodic migraine; MOH, medication overuse headache; MRS, magnetic resonance spectroscopy.

Table 1 Comparisons of demographics and clinical characteristics between episodic and chronic migraine patients and normal controls

|                        | C (n = 16) | EM (n = 25) | CM (n = 24) | P    |
|------------------------|-----------|------------|------------|------|
| Age, years             | 30.75 ± 5.98 | 37.16 ± 14.02 | 37.25 ± 15.15 | 0.236 |
| Female, n (%)          | 8 (50.00)   | 19 (76.00)  | 16 (66.67)  | 0.237 |
| Age at onset, years    | NA         | 23.30 ± 9.78 | 20.17 ± 10.63 | 0.288 |
| Disease duration, years| NA         | 14.74 ± 10.15 | 12.08 ± 9.07  | 0.340 |
| Headache intensitya    | NA         | 6.88 ± 1.92  | 7.25 ± 1.22   | 0.428 |
| Headache frequency, days/month | NA | 6.88 ± 3.56  | 21.88 ± 6.69  | <0.001*** |
| BMI (kg/m²)            | 21.67 ± 2.72 | 22.51 ± 3.50 | 22.29 ± 3.59  | 0.564 |
| MIDAs (0–270)          | NA         | 52.60 ± 37.30 | 101.00 ± 63.16 | 0.033* |
| HIT-6 (36–78)          | NA         | 68.40 ± 5.64  | 62.92 ± 9.80  | 0.131 |
| PHQ-9 (0–27)           | NA         | 4.60 ± 3.72   | 8.23 ± 5.56   | 0.090 |
| GAD-7 (0–21)           | NA         | 5.10 ± 5.43   | 6.31 ± 5.50   | 0.605 |
| PSQI (0–21)            | NA         | 9.50 ± 4.58   | 7.92 ± 4.56   | 0.428 |
| MoCA (0–30)            | NA         | 27.78 ± 1.86  | 27.33 ± 2.06  | 0.616 |

C Control, EM Episodic migraine, CM Chronic migraine, NA Not applicable, BMI Body Mass Index, MIDAs Migraine Disability Assessment Scale, HIT-6 Headache Impact Test-6, PHQ-9 Patient Health Questionnaire-9, GAD-7 Generalized Anxiety Disorder-7, PSQI Pittsburgh Sleep Quality Index, MoCA Montreal Cognitive Assessment

* P < 0.05, Statistically significant
*** P < 0.001, Statistically significant

a Headache intensity in a 0–10 numerical rating scale
Table 2: Comparisons of demographics and clinical characteristics between CM with and without MOH

|                           | Without MOH (n = 12) | With MOH (n = 12) | P    |
|---------------------------|----------------------|-------------------|------|
| Age, years                | 32.25 ± 17.96        | 43.25 ± 8.89      | 0.054|
| Female, n (%)             | 6 (50.00)            | 10 (83.33)        | 0.091|
| Age at onset, years       | 19.25 ± 12.71        | 21.08 ± 8.52      | 0.682|
| Disease duration, years   | 12.08 ± 9.28         | 22.17 ± 12.41     | 0.034*|
| Headache intensity a      | 6.92 ± 1.24          | 7.58 ± 1.16       | 0.188|
| Headache frequency, days/month | 18.75 ± 5.17     | 25.00 ± 6.74      | 0.018*|
| BMI (kg/m²)               | 22.09 ± 2.70         | 22.48 ± 4.42      | 0.798|
| MIDAs (0–270)             | 108.57 ± 73.51       | 92.17 ± 54.00     | 0.661|
| HIT-6 (36–78)             | 65.57 ± 6.24         | 59.83 ± 12.75     | 0.313|
| PHQ-9 (0–27)              | 9.14 ± 6.09          | 7.17 ± 5.19       | 0.546|
| GAD-7 (0–21)              | 7.29 ± 6.37          | 5.17 ± 4.58       | 0.512|
| PSQI (0–21)               | 5.86 ± 4.14          | 10.80 ± 3.70      | 0.059|
| MoCA (0–30)               | 27.57 ± 1.40         | 27.00 ± 2.92      | 0.658|

MO: Medication overuse, BMI: Body Mass Index, MIDAs: Migraine Disability Assessment Scale, HIT-6: Headache Impact Test-6, PHQ-9: Patient Health Questionnaire-9, GAD-7: Generalized Anxiety Disorder-7, PSQI: Pittsburgh Sleep Quality Index, MoCA: Montreal Cognitive Assessment

* P < 0.05, Statistically significant;

*a Headache intensity in a 0–10 numerical rating scale

Fig. 3: Brain neurochemical levels of the HC, EM, and CM groups. a) GABA/water (international units [i.u.]) in the PAG and DN of the HC, EM, and CM groups. b) GABA/Cr in the PAG and DN of the HC, EM, and CM groups. c) Glx/water (i.u.) in the PAG and DN of the HC, EM, and CM groups. d) Glx/Cr in the PAG and DN of the HC, EM, and CM groups. *P < 0.05 (statistically significant). Abbreviations: HC, healthy control; EM, episodic migraine; CM, chronic migraine; PAG, periaqueductal gray; DN, dentate nucleus; Cr, creatine; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine
groups. However, the level of Glx/water ($p=0.049$) in the PAG of the CM group was significantly higher than that of the control group. Patients with CM had a significantly higher Glx/Cr ratio in the PAG than the control group ($P=0.080$).

**Brain neurochemical levels of patients having CM with and without MOH**

The neurochemical levels in the PAG and DN of the three groups are shown in Fig. 4. Our results showed that GABA/water and GABA/Cr levels were not significantly different in the PAG and DN of the patients having CM with and without MOH. Our results also showed that Glx/water and Glx/Cr levels were not significantly different in the PAG and DN of patients having CM with and without MOH.

**Correlation between brain neurochemical levels and migraine characteristics**

During this study, we compared the correlation between migraine characteristics and different regional neurochemical levels of all patients with migraine (patients with EM and CM, $n=49$). In patients with migraine, higher GABA levels (GABA/water: $r=0.515$, $p=0.017$, $n=21$; GABA/Cr: $r=0.522$, $p=0.015$, $n=21$) in the PAG were significantly associated with poorer sleep quality (higher PHQ-9 scores) (Fig. 5A, B). Lower Glx/Cr ($r=-0.425$, $p=0.055$, $n=20$) levels in the DN were associated with more severe migraine disability (Fig. 5C), and lower GABA/water ($r=-0.424$, $p=0.062$, $n=20$) and Glx/water ($r=-0.452$, $p=0.045$, $n=20$) levels were associated with poorer sleep quality (Fig. 5D, E); however, these associations were not significant. Additionally, we found that GABA and Glx levels in the PAG and DN of all patients were not associated with any other clinical characteristics (Additional file 1: Figs. S1-S8).

**Discussion**

This study aimed to explore the pathogenesis of migraine chronification using the neurotransmitters GABA and Glx. We specifically investigated local GABA and Glx concentrations in the PAG and DN of the control, EM, and CM groups. Our results showed that GABA levels in the DN were significantly lower in the CM group than in the control group. We also found that Glx levels in the PAG were significantly higher in the CM group than in the control group. Additionally, we found that
depression, disability, and sleep quality were strongly associated with neurochemical levels.

**DN and migraine**

The cerebellum accounts for only 10% of the total volume of the brain, yet it contains more than 50% of the total number of neurons in the brain [24]. The cerebellum consists of two major parts, the cerebellar nucleus and the cortex. The cerebellar nuclei are the main output structures of the cerebellum and innervate several areas of the brainstem and forebrain [25]. The cerebellar cortex is divided, from the inside to the outside, into the granule cell layer, Purkinje cell layer, and molecular layer. Cerebellar nuclei neurons receive the majority of their inputs from GABAergic Purkinje cells that form the principal output neurons of the cerebellar cortex [26]. The DN is the largest cerebellar nucleus located lateral to the interposed nuclei. It receives input from the lateral hemisphere and cerebellar afferents that carry information from the cerebral cortex (via the pontine nuclei). It projects to the contralateral red nucleus and ventrolateral thalamic nucleus. Therefore, the DN has a pivotal role in cerebellar-related functions.

The cerebellum has canonically been implicated in various forms of motor control and coordination [27, 28]; however, recent evidence has suggested that it may

---

**Fig. 5** Associations between migraine characteristics and neurochemical levels. 

- **a** Positive correlation between GABA/water in the PAG and the PHQ-9 score ($r = 0.515, p = 0.017, n = 21$). 
- **b** Positive correlation between GABA/Cr in the PAG and the PHQ-9 score ($r = 0.522, p = 0.015, n = 21$). 
- **c** Negative correlation between Glx/Cr in the DN and the MIDAS score ($r = -0.425, p = 0.055, n = 20$). 
- **d** Negative correlation between GABA/water in the PAG and the PSQI score ($r = -0.424, p = 0.062, n = 20$). 
- **e** Negative correlation between Glx/Water in the DN and the PSQI score ($r = -0.452, p = 0.045, n = 20$).

Dots represent participants with migraine. The black regression line represents Pearson’s correlation coefficient ($r$). Gray shading represents the 95% confidence intervals of the partial correlations. Abbreviations: PAG, periaqueductal gray; DN, dentate nucleus; Cr, creatine; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine; MIDAS, migraine disability assessment scale; PHQ-9, Patient Health Questionnaire-9; PSQI, Pittsburgh Sleep Quality Index.
have a role in regulating migraine [18]. Some MRI studies of migraine showed significantly increased cerebellar activity during the ictal phase compared to that during the interictal phase [29–31]. Increased cerebellar activity has been demonstrated in response to trigeminal noxious stimuli in patients with migraine and healthy subjects [32–35]. Several structural imaging studies have found ischemic cavities, subclinical infarcts, and lesions in the cerebellar cortex and white matter in patients with migraine, suggesting that the cerebellum is particularly vulnerable to atrophy and injury [36–41]. Some studies showed that the severity of cerebellum damage was associated with the frequency and duration of migraine attacks [42, 43]. Additionally, recent studies have reported altered cerebellar functional connectivity with migraine, suggesting that the cerebellum may be involved in pain regulation [29, 44].

Cerebellar connectivity with neuronal networks is the anatomical basis of functional regulation in migraine. As one of the key structures involved in migraine pathophysiology, the spinal trigeminal nucleus receives information from trigeminal ganglion cells innervating the meninges and cranial vasculature [45]. It has also been verified that nociceptive neurons in the spinal trigeminal nucleus directly project to the cerebellum and cerebellar areas, such as the inferior olive and pontine nuclei [46–49]. Additionally, the cerebellum has also been found to be reciprocally connected to the PAG [50, 51], and receive input from the locus coeruleus and parabrachial nucleus [52, 53], which are thought to have the capacity to modulate the activity of the trigeminal pathway. Studies of neurochemical levels of patients with migraine have provided additional evidence elucidating the pathological mechanisms. Other studies have also reported varying neurochemical levels in different brain regions of patients with migraine [15]. However, no studies of the role of GABA and Glx in the cerebellar DN with migraine have been reported. During this study, we found that the level of GABA in the DN of the CM group was significantly lower than that of the control group; however, there was no significant difference between the EM and control groups. This suggests that the decreased GABA level in the DN may weaken the inhibitory role of the cerebellum in pain regulation, thus participating in the chronic process of migraine.

**PAG and migraine**

The PAG receives afferent information from nociceptive neurons and projects it to the thalamic nucleus, which is an important part of the ascending pain processing. The PAG also regulates pain sensations by projecting down to the rostroventromedial medulla and trigemino-cervical complex [16]. The PAG is divided into four functional subdivisions, the dorsomedial PAG, dorsolateral PAG, lateral PAG, and ventrolateral PAG. Furthermore, within these separate subdivisions, there are differences in their responses to opioids and development of tolerance to analgesics and in the dual role of the ascending and descending pathways or the role of only the descending pathway. The PAG represents one of the most significant elements of the endogenous descending modulatory system and has attracted increasing attention regarding its role in migraine mechanisms. Several studies have reported structural changes in the PAG, such as increased volume, lesions, abnormal diffusion tensor imaging results, and iron deposition, in patients with migraine [54, 55]. Functional imaging has also indicated changes in hemodynamics and functional connectivity in the PAG of patients with migraine [54, 56, 57]. Few studies have examined the neurochemical metabolism of the PAG with EM and CM. Only Wang et al. reported the contents of N-acetylaspartate and choline in the PAG of healthy controls and patients with EM and CM; however, no significant differences were observed [58]. During this study, we found that the level of Glx in the PAG was significantly higher in patients with CM than in controls; however, this trend was not observed for patients with EM. Animal experiments have demonstrated that activation of glutamatergic neurons or inhibition of GABAergic neurons in the ventrolateral PAG can suppress nociception [59]. However, other functional areas of the PAG appear to have opposing effects [16]. Our MRS results showed the neurochemical level of the entire PAG region and did not distinguish between different functional regions. Therefore, we can conclude that an increase in the overall Glx level in the PAG is associated with CM. The disturbance of pain conduction and analgesia in the PAG may cause migraine chronification.

**MOH and neurochemical levels**

The 1-year prevalence of MOH is 2 to 3% for the general population and at least 50% for individuals with CM overuse medication [60, 61]. The pathogenesis by which medication overuse facilitates migraine transformation is incompletely understood. Numerous studies have shown that MOH is associated with atypical structures and functions of brain regions responsible for pain processing and those that are commonly implicated in addiction [62]. Some hypotheses have been proposed, such as dysfunction of the descending antinociceptive network in the brainstem and disturbance of the serotonin system [63]. However, our results failed to show a difference in neurochemical levels of patients having CM with and without MOH, which is consistent with the conclusions of previous studies [58].
Headache characteristics and neurochemical levels

Correlations between neurochemical levels and migraine characteristics remain unclear. Peek et al. demonstrated that improvements in migraine frequency, intensity, and disability are associated with increased GABA+ levels in the anterior cingulate cortex [64]. Bell et al. found that higher glutamate levels in the thalamus and higher GABA/Glx ratios in the sensorimotor cortex were associated with longer durations of pediatric migraine [10]. Additionally, lower GABA levels in the sensorimotor cortex are associated with more frequent migraine attacks [10]. However, our results regarding the DN and PAG did not show this trend. Our results showed that the increased level of GABA in the PAG was positively correlated with the degree of depression, and that the Glx level in the DN was negatively correlated with migraine-associated disability. Furthermore, we found that lower levels of GABA in the PAG and Glx in the DN represented poorer sleep quality. In summary, we believe that the neurochemical levels in the DN and PAG are involved in the regulation of depression and sleep and are closely related to disability severity.

Limitations

There were some limitations in this study. First, the ROIs placed in the target regions could not be avoided the involvement of surrounding structures. Therefore, we could not be certain about the exact relevant substrate within the DN and PAG, but we believe the results could reflect the relative changes in these regions. Additionally, the resolution during scanning of the region of interest was limited; therefore, specific functional areas and nuclei could not be distinguished. Furthermore, as a single-center cross-sectional study, the results of the current study can’t provide the information about the changes of these neurochemical levels during a continuum of chronicification progression and/or whether they are reversible. Multicenter studies with large study populations are required to validate the role of neurochemical levels in the migraine diagnosis.

Conclusion

The pathogenesis of migraine chronification is not yet fully understood. Most relevant studies have focused on structural or functional imaging, omics, and immune inflammation; few have focused on the neurochemical level. MRS, as a noninvasive craniocerebral detection technique, provides a basis for obtaining the neurochemical level of the human brain. The findings of this study indicated that GABA and Glx levels in the DN and PAG may have a pertinent role in migraine chronification. These abnormal neurochemical levels may serve as potential markers of migraine chronification and provide new evidence regarding the monitoring and treatment of CM.

Abbreviations

CM: Chronic migraine; Cr: Creatine; DN: Dentate nucleus; EM: Episodic migraine; GABA: Gamma-aminobutyric acid; GAD-7: Generalized Anxiety Disorder-7; Glx: Glutamate and glutamine; ICHD-3: International Classification of Headache Diseases, 3rd edition; MIDAS: Migraine disability assessment scale; MoCA: Montreal Cognitive Assessment; MOH: Medication overuse headache; MRI: Magnetic resonance imaging; MRS: Magnetic resonance spectroscopy; PAG: Periaqueductal gray; PHQ-9: Patient Health Questionnaire-9; PSQI: Pittsburgh Sleep Quality Index.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s10194-022-01452-6.

Additional file 1: Fig. S1. Associations between headache frequency and neurochemical levels. (A) and (B) show the correlation between headache frequency and the GABA level in the PAG. (C) and (D) show the correlation between headache frequency and the Glx level in the PAG. (E) and (F) show the correlation between headache frequency and the GABA level in the DN. (G) and (H) show the correlation between headache frequency and the Glx level in the DN. Dots represent participants with migraine. The black regression line represents Pearson’s correlation coefficient (r). Gray shading represents the 95% confidence intervals of the partial correlations. PAG, periaqueductal gray; DN, dentate nucleus; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine.

Fig. S2. Associations between disease duration and neurochemical levels. (A) and (B) show the correlation between disease duration and the GABA level in the PAG. (C) and (D) show the correlation between disease duration and the Glx level in the PAG. (E) and (F) show the correlation between disease duration and the GABA level in the DN. (G) and (H) show the correlation between disease duration and the Glx level in the DN. Dots represent participants with migraine. The black regression line represents Pearson’s correlation coefficient (r). Gray shading represents the 95% confidence intervals of the partial correlations. PAG, periaqueductal gray; DN, dentate nucleus; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine.

Fig. S3. Associations between the MIDAS score and neurochemical levels. (A) and (B) show the correlation between the MIDAS score and GABA level in the PAG. (C) and (D) show the correlation between the MIDAS score and Glx level in the PAG. (E) and (F) show the correlation between the MIDAS score and GABA level in the DN. (G) and (H) show the correlation between the MIDAS score and Glx level in the DN. Dots represent participants with migraine. The black regression line represents Pearson’s correlation coefficient (r). Gray shading represents the 95% confidence intervals of the partial correlations. MIDAS, migraine disability assessment scale; PAG, periaqueductal gray; DN, dentate nucleus; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine.

Fig. S4. Associations between the HIT-6 score and neurochemical levels. (A) and (B) show the correlation between the HIT-6 score and GABA level in the PAG. (C) and (D) show the correlation between the HIT-6 score and Glx level in the PAG. (E) and (F) show the correlation between the HIT-6 score and GABA level in the DN. (G) and (H) show the correlation between the HIT-6 score and Glx level in the DN. Dots represent participants with migraine. The black regression line represents Pearson’s correlation coefficient (r). Gray shading represents the 95% confidence intervals of the partial correlations. HIT-6, Headache Impact Test; PAG, periaqueductal gray; DN, dentate nucleus; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine.

Fig. S5. Associations between the PHQ-9 score and neurochemical levels. (A) and (B) show the correlation between the PHQ-9 score and GABA level in the PAG. (C) and (D) show the correlation between the PHQ-9 score and Glx level in the PAG. (E) and (F) show the correlation between the PHQ-9 score and GABA level in the DN. (G) and (H) show the correlation between the PHQ-9 score and Glx level in the DN. Dots represent participants with migraine. The black regression line represents Pearson’s correlation coefficient (r). Gray shading represents the 95% confidence intervals of the partial correlations. PHQ-9: Patient Health Questionnaire-9; PSQI: Pittsburgh Sleep Quality Index.
coefficient (r). Gray shading represents the 95% confidence intervals of the partial correlations. Generalized Anxiety Disorder-7; PAG, periaqueductal gray; DN, dentate nucleus; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine. **Fig. S5.** Associations between the GAD-7 score and neurochemical levels. (A) and (B) show the correlation between the GAD-7 score and GABA level in the PAG. (C) and (D) show the correlation between the GAD-7 score and Glx level in the PAG. (E) and (F) show the correlation between the GAD-7 score and GABA level in the DN. (G) and (H) show the correlation between the GAD-7 score and Glx level in the DN. Dots represent participants with migraine. The black regression line represents Pearson’s correlation coefficient (r). Gray shading represents the 95% confidence intervals of the partial correlations. Generalized Anxiety Disorder-7; PAG, periaqueductal gray; DN, dentate nucleus; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine. **Fig. S6.** Associations between the MoCA score and neurochemical levels. (A) and (B) show the correlation between the MoCA score and GABA level in the PAG. (C) and (D) show the correlation between the MoCA score and Glx level in the PAG. (E) and (F) show the correlation between the MoCA score and GABA level in the DN. (G) and (H) show the correlation between the MoCA score and Glx level in the DN. Dots represent participants with migraine. The black regression line represents Pearson’s correlation coefficient (r). Gray shading represents the 95% confidence intervals of the partial correlations. MoCA, Montreal Cognitive Assessment; PAG, periaqueductal gray; DN, dentate nucleus; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine. **Fig. S7.** Associations between the MoCA score and neurochemical levels. (A) and (B) show the correlation between the MoCA score and GABA level in the PAG. (C) and (D) show the correlation between the MoCA score and Glx level in the PAG. (E) and (F) show the correlation between the MoCA score and GABA level in the DN. (G) and (H) show the correlation between the MoCA score and Glx level in the DN. Dots represent participants with migraine. The black regression line represents Pearson’s correlation coefficient (r). Gray shading represents the 95% confidence intervals of the partial correlations. MoCA, Montreal Cognitive Assessment; PAG, periaqueductal gray; DN, dentate nucleus; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine.

Acknowledgements
This work was supported by a team from the Tiantan Neuroimaging Center of Excellence, China National Clinical Research Center for Neurological Diseases. We appreciate the continuous support of the General Electric Company and physicians at the Headache Center, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University.

Authors’ contributions
WW, YGW, and BBS supported the conception and design of this project. XYZ, physicians at the Headache Center, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University. No.1 Tongji Nan Road, Beijing Economic Technological Development Area, Beijing 10070, China.

Acknowledgements
This work was supported by a team from the Tiantan Neuroimaging Center of Excellence, China National Clinical Research Center for Neurological Diseases. We appreciate the continuous support of the General Electric Company and physicians at the Headache Center, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University.

Authors’ contributions
WW, YGW, and BBS supported the conception and design of this project. XYZ, physicians at the Headache Center, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University. No.1 Tongji Nan Road, Beijing Economic Technological Development Area, Beijing 10070, China.

Availability of data and materials
Data can be made available upon request.

Declarations
Ethics approval and consent to participate All participants received a complete description of the study and granted written informed consent. This study had been registry on Clinical Trial (NCT03534927) and ethical approval was granted by Beijing Tiantan Hospital, Capital Medical University (no. KY2022-044).

Consent for publication
All authors have agreed to the current submission.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Headache Center, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing 100070, China. 2 Tiantan Neuroimaging Center of Excellence, China National Clinical Research Center for Neurological Diseases, No.119 South Fourth Ring West Road, Fengtai District, Beijing 100070, China. 3 Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing 100070, China. 4 Department of Neurology, The First Affiliated Hospital of Zhengzhou University, No.1, Jianshe East Road, Zhengzhou, Henan Province 450000, China. 5 GE Healthcare, No.1 Tongji Nan Road, Beijing Economic Technological Development Area, Beijing 10070, China.

Received: 8 April 2022 Accepted: 4 July 2022 Published online: 15 July 2022

References
1. Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23(1):34
2. The International Classification of Headache Disorders (2013) 3rd edition (beta version). Cephalalgia 33(9):629–808
3. Filippi M, Messina R (2019) The chronic migraine brain: what have we learned from neuroimaging? Front Neurol 10:1356
4. Schwedt TJ (2014) Chronic migraine. BMJ (Clinical research ed) ed) 348:g1416
5. Andreu AP, Edvinsson L (2019) Mechanisms of migraine as a chronic evolutive condition. J Headache Pain 20(1):117
6. Quintas M, Neto JL, Pereira-Monteiro J, Barros J, Sequeiros J, Sousa A, Alonso I, Lemos C (2013) Interaction between γ-aminobutyric acid A receptor genes: new evidence in migraine susceptibility. PLoS One 8(9):e74087
7. Chen T, Murrell M, Fowdar J, Roy B, Grealy R, Griffiths LR (2012) Investigation of the role of the GABRG2 gene variant in migraine. J Neurol Sci 318(1–2):112–114
8. Plummer PN, Colson NJ, Lewohl JM, MacKay RK, Fernandez F, Haupt LM, Griffiths LR (2011) Significant differences in gene expression of GABA receptors in peripheral blood leukocytes of migraineurs. Gene 490(1–2):32–36
9. Ziemann R, Wijnen JP, Webb A, Onderwater GLJ, Ronen I, Ferrari MD, Kan HE, Terwindt GM, Kruit MC (2017) Cortical glutamate in migraine. Brain : a journal of neuroscience 140(7):1859–1871
10. Bell T, Stroke M, Khaira A, Webb M, Noel M, Amoozegar F, Harris AD (2021) GABA and glutamate in pediatric migraine. Pain 162(1):300–308
11. Agullà ME, Lagopoulou L, Leaver AM, Rebbeck T, Hübischer M, Brennan PM, Refshauge KM (2015) Elevated levels of GABA-A in migraine detected using (1) H-MRS. NMR Biomed 28(7):890–897
12. Bridge H, Stagg CJ, Near J, Lau CI, Zinsner A, Cader MZ (2015) Altered neurochemical coupling in the occipital cortex in migraine with visual aura. Cephalalgia : Int J Headache 35(11):1025–1030
13. Bigal ME, Hetherington H, Pan J, Tsang A, Grosberg B, Avdievich N, Friedman B, Lipton RB (2008) Occipital levels of GABA in migraine detected using [1 H-MRS. NMR Biomed 21(7):890–897
14. Russo A, Silvestro M, Tessitore A, Tedeschi G (2018) Advances in migraine neuroimaging and clinical utility: from the MRI to the bedside. Expert Rev Neurother 18(7):533–544
15. Younis S, Hougaard A, Vestergaard MB, Larsson HBW, Ashina M (2017) Migraine and magnetic resonance spectroscopy: a systematic review. Curr Opin Neurol 30(3):246–262
16. Vila-Pueyo M, Hoffmann J, Romero-Reyes M, Akerman S (2019) Brain function and structure related to headache: Brainstem structure and function in headache. Cephalalgia : Int J Headache 39(13):1635–1660
17. Messina R, Filippi M, Goadsby PJ (2018) Recent advances in headache neuroimaging. Curr Opin Neurol 31(4):370–385
18. Kros L, Angueya Aristizábal CA, Khodakhah K (2018) Cerebellar involvement in migraine. Cephalalgia 38(11):1782–1791
